AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways. Their peptide drug candidates tap into the body’s powerful mechanisms of maintaining homeostasis, the fundamental principle of biology to seek and maintain a condition of equilibrium or stability.

Biotechnology

AsclepiX Therapeutics

Robert J. Dempsey

Jill Vazzano Tierney

Teams at AsclepiX Therapeutics

Scientific and Clinical Development

Leadership Team